ערך בספרים למניה: Pieris Pharmaceuticals (PVLA)

This daily price chart for Pieris Pharmaceuticals (PVLA) illustrates the price action of the asset, which is currently valued at 14.92. The biotech firm is currently undergoing a rigorous internal restructuring and a freeze on projects following the collapse of a key alliance. The business relies on the commercialization of unique protein technologies to combat oncology and asthma. Previously, Pieris Pharmaceuticals (PVLA) developed therapeutic methods in collaboration with the world's largest pharma behemoths.

Book value per share reflects the actual value of the issuer's net assets, excluding market fluctuations. This metric is calculated as the difference between all assets and liabilities, divided by the number of shares. The trend in reference book value per share demonstrates the rate of equity preservation. For Pieris Pharmaceuticals (PVLA), this metric is critical during the restructuring period following the termination of its partnership. It allows for an assessment of the residual value of assets available for licensing to ensure business survival.